;PMID: 7947263 ;source_file_1232.mrg ;Release 0.9 of PennBioIE ;Funded by NSF ITR EIA-0205448 ;0)section:[e:0..36] = [t:0..36] ;1)sentence:[e:41..174] = [t:41..174] ;2)section:[e:178..230] = [t:178..230] ;3)section:[e:234..301] = [t:234..301] ;4)sentence:[e:305..437] = [t:305..437] ;5)sentence:[e:438..727] = [t:438..727] ;6)sentence:[e:728..931] = [t:728..931] ;7)sentence:[e:932..1039] = [t:932..1039] ;8)section:[e:1043..1087] = [t:1043..1087] ;section 0 Span:0..36 ;Br J Haematol 1994 Jun;87(2):235-42 (SEC (FRAG (NNP:[0..2] Br) (NNP:[3..4] J) (NNP:[5..13] Haematol) (CD:[15..19] 1994) (CC:[20..27] Jun;87-LRB-) (CD:[27..28] 2) (-RRB-:[28..29] -RRB-) (CD:[29..33] :235) (::[33..34] -) (CD:[34..36] 42))) ;sentence 1 Span:41..174 ;Establishment and characterization of a novel myeloid cell line from the bone ; marrow of a patient with the myelodysplastic syndrome. ;[87..104]:malignancy:"myeloid cell line" ;[149..173]:malignancy:"myelodysplastic syndrome" (SENT (NP-HLN (NP (NN:[41..54] Establishment) (CC:[55..58] and) (NN:[59..75] characterization)) (PP (IN:[76..78] of) (NP (NP (DT:[79..80] a) (JJ:[81..86] novel) (JJ:[87..94] myeloid) (NN:[95..99] cell) (NN:[100..104] line)) (PP (IN:[105..109] from) (NP (NP (DT:[110..113] the) (NN:[114..118] bone) (NN:[120..126] marrow)) (PP (IN:[127..129] of) (NP (NP (DT:[130..131] a) (NN:[132..139] patient)) (PP (IN:[140..144] with) (NP (DT:[145..148] the) (JJ:[149..164] myelodysplastic) (NN:[165..173] syndrome))))))))) (.:[173..174] .))) ;section 2 Span:178..230 ;Tohyama K, Tsutani H, Ueda T, Nakamura T, Yoshida Y. (SEC (FRAG (NNP:[178..185] Tohyama) (NNP:[186..187] K) (,:[187..188] ,) (NNP:[189..196] Tsutani) (NNP:[197..198] H) (,:[198..199] ,) (NNP:[200..204] Ueda) (NNP:[205..206] T) (,:[206..207] ,) (NNP:[208..216] Nakamura) (NNP:[217..218] T) (,:[218..219] ,) (NNP:[220..227] Yoshida) (NNP:[228..230] Y.))) ;section 3 Span:234..301 ;First Department of Internal Medicine, Fukui Medical School, Japan. (SEC (FRAG (NNP:[234..239] First) (NNP:[240..250] Department) (IN:[251..253] of) (NNP:[254..262] Internal) (NNP:[263..271] Medicine) (,:[271..272] ,) (NNP:[273..278] Fukui) (NNP:[279..286] Medical) (NNP:[287..293] School) (,:[293..294] ,) (NNP:[295..300] Japan) (.:[300..301] .))) ;sentence 4 Span:305..437 ;A novel long-term cultured myeloid cell line was established from the bone ;marrow of a patient with myelodysplastic syndrome (MDS). ;[332..349]:malignancy:"myeloid cell line" ;[406..430]:malignancy:"myelodysplastic syndrome" ;[432..435]:malignancy:"MDS" (SENT (S (NP-SBJ-1 (DT:[305..306] A) (JJ:[307..312] novel) (NML (JJ:[313..317] long) (HYPH:[317..318] -) (NN:[318..322] term)) (VBN:[323..331] cultured) (JJ:[332..339] myeloid) (NN:[340..344] cell) (NN:[345..349] line)) (VP (VBD:[350..353] was) (VP (VBN:[354..365] established) (NP-1 (-NONE-:[365..365] *)) (PP (IN:[366..370] from) (NP (NP (DT:[371..374] the) (NN:[375..379] bone) (NN:[381..387] marrow)) (PP (IN:[388..390] of) (NP (NP (DT:[391..392] a) (NN:[393..400] patient)) (PP (IN:[401..405] with) (NP (NP (JJ:[406..421] myelodysplastic) (NN:[422..430] syndrome)) (NP (-LRB-:[431..432] -LRB-) (NN:[432..435] MDS) (-RRB-:[435..436] -RRB-)))))))))) (.:[436..437] .))) ;sentence 5 Span:438..727 ;This cell line, designated MDS92, proliferated in the presence of ;interleukin-3 or granulocyte-macrophage colony-stimulating factor and ;transiently in the presence of Steel factor, with a tendency for gradual ;maturation, and formed myeloid colonies in the semi-solid culture ;condition. ;[443..452]:malignancy:"cell line" ;[466..471]:malignancy:"MDS92" ;[505..518]:gene-protein:"interleukin-3" ;[523..571]:gene-protein:"granulocyte-macrophage colony-stimulating factor" ;[608..620]:gene-protein:"Steel factor" (SENT (S (NP-SBJ (NP (DT:[438..442] This) (NN:[443..447] cell) (NN:[448..452] line)) (,:[452..453] ,) (VP (VBN:[455..465] designated) (S (NP-SBJ (-NONE-:[465..465] *)) (NP-PRD (NN:[466..471] MDS92))))) (,:[471..472] ,) (VP (VP (VP (VBD:[473..485] proliferated) (PP=1 (IN:[486..488] in) (NP (NP (DT:[489..492] the) (NN:[493..501] presence)) (PP (IN:[502..504] of) (NP (NP (NN:[505..518] interleukin-3)) (CC:[519..521] or) (NP (NML (NN:[523..534] granulocyte) (HYPH:[534..535] -) (NN:[535..545] macrophage)) (NML (NN:[546..552] colony) (HYPH:[552..553] -) (VBG:[553..564] stimulating)) (NN:[565..571] factor))))))) (CC:[572..575] and) (VP (ADVP (RB:[576..587] transiently)) (PP=1 (IN:[588..590] in) (NP (NP (DT:[591..594] the) (NN:[595..603] presence)) (PP (IN:[605..607] of) (NP (NNP:[608..613] Steel) (NN:[614..620] factor))))) (,:[620..621] ,) (PP (IN:[622..626] with) (NP (NP (DT:[627..628] a) (NN:[629..637] tendency)) (PP (IN:[638..641] for) (NP (JJ:[642..649] gradual) (NN:[650..660] maturation))))))) (,:[660..661] ,) (CC:[662..665] and) (VP (VBD:[666..672] formed) (NP (JJ:[673..680] myeloid) (NNS:[682..690] colonies)) (PP (IN:[691..693] in) (NP (DT:[694..697] the) (NML (ADJP (AFX:[698..702] semi) (HYPH:[702..703] -) (JJ:[703..708] solid)) (NN:[709..716] culture)) (NN:[717..726] condition))))) (.:[726..727] .))) ;sentence 6 Span:728..931 ;In addition, the MDS92 cell line represented rather complicated karyotypic ;abnormalities including the deletion of fifth and seventh chromosomes and a ;point mutation at codon 12 of the N-ras oncogene. ;[745..760]:malignancy:"MDS92 cell line" ;[832..840]:variation-type:"deletion" ;[845..850]...[855..862]...[863..874]:variation-location:"fifth"..."seventh".. ;."chromosomes" ;[881..895]:variation-type:"point mutation" ;[899..907]:variation-location:"codon 12" ;[915..920]:gene-rna:"N-ras" (SENT (S (PP (IN:[728..730] In) (NP (NN:[731..739] addition))) (,:[739..740] ,) (NP-SBJ (DT:[741..744] the) (NN:[745..750] MDS92) (NN:[751..755] cell) (NN:[756..760] line)) (VP (VBD:[762..773] represented) (NP (NP (RB:[774..780] rather) (JJ:[781..792] complicated) (JJ:[793..803] karyotypic) (NNS:[804..817] abnormalities)) (PP (VBG:[818..827] including) (NP (NP (NP (DT:[828..831] the) (NN:[832..840] deletion)) (PP (IN:[842..844] of) (NP (NP (JJ:[845..850] fifth) (NML-1 (-NONE-:[850..850] *P*))) (CC:[851..854] and) (NP (JJ:[855..862] seventh) (NML-1 (NNS:[863..874] chromosomes)))))) (CC:[875..878] and) (NP (NP (DT:[879..880] a) (NN:[881..886] point) (NN:[887..895] mutation)) (PP-LOC (IN:[896..898] at) (NP (NP (NN:[899..904] codon) (CD:[905..907] 12)) (PP (IN:[908..910] of) (NP (DT:[911..914] the) (NN:[915..920] N-ras) (NN:[922..930] oncogene)))))))))) (.:[930..931] .))) ;sentence 7 Span:932..1039 ;These characteristics of the MDS92 cell line are exclusively compatible with ;the property of preleukaemia. ;[961..976]:malignancy:"MDS92 cell line" ;[1026..1038]:malignancy:"preleukaemia" (SENT (S (NP-SBJ (NP (DT:[932..937] These) (NNS:[938..953] characteristics)) (PP (IN:[954..956] of) (NP (DT:[957..960] the) (NN:[961..966] MDS92) (NN:[967..971] cell) (NN:[972..976] line)))) (VP (VBP:[977..980] are) (ADVP (RB:[981..992] exclusively)) (ADJP-PRD (JJ:[994..1004] compatible) (PP (IN:[1005..1009] with) (NP (NP (DT:[1010..1013] the) (NN:[1014..1022] property)) (PP (IN:[1023..1025] of) (NP (NN:[1026..1038] preleukaemia))))))) (.:[1038..1039] .))) ;section 8 Span:1043..1087 ;PMID: 7947263 [PubMed - indexed for MEDLINE] (SEC (FRAG (NNP:[1043..1047] PMID) (::[1047..1048] :) (CD:[1049..1056] 7947263) (NN:[1057..1058] -LSB-) (NNP:[1058..1064] PubMed) (::[1065..1066] -) (NN:[1067..1074] indexed) (IN:[1075..1078] for) (NNP:[1079..1087] MEDLINE-RSB-)))